SwanBio Therapeutics is researching and developing novel gene therapies for people living with neurological disorders. Historically, neurological disorders have been challenging targets for drug development. To create safe and effective drugs for diseases involving the spinal cord, highly targeted therapies and delivery strategies to deliver them to the nervous tissues are required. Through the use of adeno-associated viruses (AAVs), SwanBio is creating therapies that deliver genetic corrections to replace damaged games and treat the root cause of disease. This type of therapy has the potential to provide patients with durable responses rather than only symptom management. SwanBio’s lead program, SBT101, aims to treat patients with adrenomyeloneuropathy.

SwanBio Therapeutics

Spur Therapeutics (Formerly Freeline) Announces New Name and Brand - Yahoo Finance

SwanBio Therapeutics Announces $56 Million Series B Financing to Advance Novel Gene Therapies for Neurological Conditions - Business Wire

Gene therapy developer SwanBio to narrow research focus, lay off half its workforce - The Business Journals

 Gene therapy developer SwanBio to narrow research focus, lay off half its workforce 

We’re getting ready to honor #RareDiseaseDay later this month with a conversation between our co-founders about WHY.
 
Why does SwanBio exist?
Why are we so committed to developing a gene therapy for #AMN?
Why is drug development for rare diseases so different than more common conditions?
 
Thank you Florian Eichler for joining us to remind us that 'rare' does not mean different, separate, or alone.

#showyourstripes
#adrenomyeloneuropathy
#RDD24

Our CSO Karen Kozarsky, Ph.D. is pleased to be joining other industry experts next month (Thurs, Feb 15) to discuss #genetherapy manufacturing. Register today!

We kicked off February by gathering some of our Swans to celebrate our 6th birthday. Thank you to our extended Pond who has supported us along the way: our team members, research partners, clinicians, clinical trial sites, and members of the AMN community. We are incredibly proud of what we've learned about #adrenomyeloneuropathy and AAV #genetherapy over the past 6 years, with your collaboration and shared insights.

Cheers to many more!

Don’t miss our must-see webinar with Endpoints News featuring notable industry leaders to discuss “7 questions gene therapy developers should ask their CDMO (and what they will ask you!)"
 
We’ll delve into the key questions around yield, commercial readiness, validated scale-down models, automation of analytical assays, and more.
 
Speakers:
David Dismuke
Jenny Holt
Karen Kozarsky, Ph.D.
John Maslowski
 
Register here ➡️ https://hubs.li/Q02gjHZp0

We are excited to share that SwanBio is now part of Spur Therapeutics. Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more at spurtherapeutics.com. 

Deals Report: Syncona merging Freeline, SwanBio to form Spur - BioCentury

 40 Under 40: Cindy Hanna, SwanBio Therapeutics 

 Syncona invests in $56 million Series B financing of SwanBio Therapeutics 

Of the 6000+ known rare diseases, why was SwanBio founded to focus on AMN? Listen & learn as we strive to every day – and especially today, #RareDiseaseDay.
 
We are indebted to the adrenomyeloneuropathy community for the trust and faith they have put in our team to develop the first clinical-stage gene therapy for this devastating disease. We constantly strive to better understand the impact of AMN on patients, caregivers, and families in order to make a meaningful difference.
 
#RDD2024 

LinkedIn

 SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy 

Syncona blames £80M drop in its biotech valuations on 'challenging market' - Fierce Biotech

 Syncona Ltd. and Partners Innovation Fund led the Series A expansion 

 SwanBio Evolves Leadership Team with Appointment of Executive Chair and Chief Operating Officer 

This Thurs, Feb 15: Our Co-Founder and CSO Karen Kozarsky, Ph.D. will join other industry leaders to discuss #genetherapy manufacturing. Register below!

40 Under 40: Cindy Hanna, SwanBio Therapeutics - The Business Journals

Syncona melds two gene therapy biotechs for better shot at new nervous system treatments - BioPharma Dive

 SwanBio Therapeutics Appoints Steven Zelenkofske, DO, as Chief Medical Officer 

Freeline Therapeutics Rebrands to Spur Therapeutics - Contract Pharma

Syncona targets AAV success through creation of Spur Therapeutics - BioProcess Insider

 SwanBio Therapeutics to Present Preclinical Data on Lead Candidate 


                                      Our Leadership 
                                    

 SwanBio Therapeutics Raises $52M in Series A 

SwanBio Advances to Higher-Dose Cohort in First-in-Human Study of Gene Therapy for Adrenomyeloneuropathy - Business Wire

SwanBio Therapeutics

Business:

Drug notes:

About: